Drugs / ABT-806i
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01472003 | Oct 2011 → Dec 2012 | cancer | AbbVie | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-806i | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01472003 ↗ |
| Known as | 111In-ABT-806 | “An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types” NCT01472003 ↗ |
| Known as | INDIUM 111 ABT 806 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650370 ↗ |
| Route | Intravenous | “ABT-806i will be administered by intravenous infusion.” NCT01472003 ↗ |
| Target | EGFR | “ABT-806i allows for real-time imaging of EGFR conformational expression in tumors” PMID 33509972 ↗ Jan 2021 |